Daniel Paredes, PhD
Research Associate Professor
Professional Information
Biography
Dr. Daniel Paredes serves as a Research Associate Professor at the Knoebel Institute for Healthy Aging and the Ritchie School of Engineering and Computer Science at the University of Denver. With extensive experience in molecular pharmacology, neuroscience, and bioengineering, Dr. Paredes' research is focused on developing innovative diagnostic technologies and therapeutic strategies for neurodegenerative diseases, aging, and brain injuries. His current work emphasizes the integration of biomarkers, AI-driven diagnostics, and stem cell-based approaches to tackle conditions such as Alzheimer's, Parkinson's, Huntington's, and vascular dementia. Most recently, Dr. Paredes is exploring the therapeutic potential of Multilineage-differentiating Stress Enduring (MUSE) cells in pre-clinical models of Parkinson's disease.
Specialization
Neurodegeneration, Neurochemistry, Stem Cell (MUSE CELLS).
Education
Postdoctoral Fellowship (2007-2009): ; Section on Molecular Neurobiology, National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD.; Ph.D. in Molecular Pharmacology, Physiology, and Neuroscience (2007): ; University of South Florida, Tampa, FL.; Master's in Biomedical Sciences (2005): ; University of South Florida, Tampa, FL.
Research & Publications
- Sandberg, A. et al., including Paredes, D.A. (2025). Polyamine biosynthesis dysregulation in Alzheimer's disease and Down syndrome cellular models. bioRxiv. - Basya, C.Z. et al., including Paredes, D.A. (2025). A Brain-Penetrating Foldamer Rescues Aβ Aggregation-Associated Alzheimer's Disease Phenotypes in In Vivo Models. ACS Chemical Neuroscience, 16(7):1309-1322. - Pak, H.H. et al., including Paredes, D.A. (2024). Non-canonical metabolic and molecular effects of calorie restriction revealed by varying temporal conditions. Cell Reports, 43(9):114663. - Ahmed, J. et al., including Paredes, D.A. (2022). Foldamers Reveal and Validate Novel Therapeutic Targets Associated with Toxic α-Synuclein Self-Assembly. Nature Communications, 13:2273.